85% of COVID deaths could have been spared with an intensive early treatment program at home continued through hospitalization, including monoclonal antibodies and Ivermectin.

Nov 7, 2026

Previously: 85% of COVID deaths could have been spared with an intensive early treatment program at home continued through hospitalization, including monoclonal antibodies and Ivermectin. [Distorted]: This is Dr. McCullough's own estimate, not a figure from any trial. Some early treatments, like monoclonal antibodies and later Paxlovid, did lower hospitalization in high-risk patients. But randomized trials such as ACTIV-6 found ivermectin no better than a placebo, and no controlled study shows his combined home-treatment program would have prevented 85% of COVID deaths. This would be wrong if a controlled study showed that intensive early treatment including ivermectin cut COVID deaths by around 85%.

Now: 85% of COVID deaths could have been spared with an intensive early treatment program at home continued through hospitalization, including monoclonal antibodies and Ivermectin. [Unverified]: The 85% figure is McCullough's counterfactual estimate. No controlled population evidence for that percentage or the full combined protocol was established here. Some components had demonstrated benefits in selected settings. TOGETHER found no primary-outcome benefit for ivermectin in early outpatients, but that trial alone does not quantify the full protocol's national counterfactual effect.

Downgrade an unvalidated counterfactual to unverified and avoid claiming a trial of one component tests the entire protocol.